Droperidol on Prevention of Cannabis Hyperemesis Syndrome

Description

The purpose of this study is to assess the efficacy of droperidol as a treatment of cannabinoid hyperemesis syndrome.

Conditions

Cannabis Hyperemesis Syndrome

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to assess the efficacy of droperidol as a treatment of cannabinoid hyperemesis syndrome.

Droperidol on Prevention of Emesis From Cannabinoid Hyperemesis Syndrome

Droperidol on Prevention of Cannabis Hyperemesis Syndrome

Condition
Cannabis Hyperemesis Syndrome
Intervention / Treatment

-

Contacts and Locations

Austintown

Mercy Health - Austintown, Austintown, Ohio, United States, 44515

Boardman

St Elizabeth Boardman Hospital, Boardman, Ohio, United States, 44512

Warren

St. Joseph-Warren Hospital, Warren, Ohio, United States, 44484

Youngstown

St Elizabeth Youngstown Hospital, Youngstown, Ohio, United States, 44501

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * aged 18 years of age or older and presenting with cannabis hyperemesis syndrome requiring intravenous medication.
  • * any patient with a contraindication to the use of droperidol
  • * Corrected QT interval on ECG greater than 440 milliseconds for males and greater than 450 milliseconds for females
  • * any prisoners
  • * pregnant females.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Mercy Health Ohio,

Todd Bolotin, MD, PRINCIPAL_INVESTIGATOR, Mercy Health

Study Record Dates

2023-01-31